Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.